The ‘4th Oncology Clinical
Trials in Emerging Regions’ (OCTER) conference will assess
the current ever changing operational, regulatory and
logistical challenges being faced when conducting oncology
clinical trials in emerging regions as well as looking at
the future role that emerging regions will play and which
of the lesser known countries will continue grow in
importance.
Some of the subjects under discussion will include –
The role of emerging regions against the
backdrop of ever tightening FDA regulations
Small pharma: fighting for attention. Examples
of oncology clinical trials being conducted in lesser
recognised countries
The CROs role in conducting oncology clinical
trials in emerging regions
Randomised trials v Single arm studies in
oncology clinical trials
Overall 34% of Phase 3 clinical trials fail –
can emerging markets reduce the failure rate or are
they contributing towards it?
Overcoming the challenges and variations of
localised regulatory procedures
Logistical challenges of conducting clinical
trials in emerging regions – what are the main
regional challenges and variations
Patient recruitment and retention in emerging
countries – challenging the frontiers
Conducting post marketing studies of oncology
clinical trials in emerging regions
Oncology clinical trials in China – a case
study of large clinical trials and the challenges
faced
The role of electronic data capture to
accelerate the completion of clinical trials
